Neurocrine Biosciences Correlations
NBIX Stock | USD 115.60 3.68 3.29% |
The current 90-days correlation between Neurocrine Biosciences and Alkermes Plc is 0.06 (i.e., Significant diversification). The correlation of Neurocrine Biosciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak. If the correlation is 0, the equities are not correlated; they are entirely random.
Neurocrine Biosciences Correlation With Market
Modest diversification
The correlation between Neurocrine Biosciences and DJI is 0.22 (i.e., Modest diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Neurocrine Biosciences and DJI in the same portfolio, assuming nothing else is changed.
Neurocrine |
Moving together with Neurocrine Stock
0.81 | SCLX | Scilex Holding | PairCorr |
0.75 | ASMB | Assembly Biosciences Earnings Call Tomorrow | PairCorr |
0.68 | CMND | Clearmind Medicine Common | PairCorr |
0.81 | CAT | Caterpillar | PairCorr |
0.67 | HD | Home Depot | PairCorr |
0.62 | DIS | Walt Disney | PairCorr |
0.77 | MSFT | Microsoft Aggressive Push | PairCorr |
Moving against Neurocrine Stock
0.86 | LUCD | Lucid Diagnostics | PairCorr |
0.68 | WM | Waste Management | PairCorr |
0.52 | PG | Procter Gamble | PairCorr |
0.42 | GE | GE Aerospace | PairCorr |
0.79 | JNJ | Johnson Johnson Sell-off Trend | PairCorr |
0.79 | T | ATT Inc Sell-off Trend | PairCorr |
0.65 | INTC | Intel Sell-off Trend | PairCorr |
0.58 | IBM | International Business | PairCorr |
0.5 | XOM | Exxon Mobil Corp Earnings Call This Week | PairCorr |
0.49 | CSCO | Cisco Systems | PairCorr |
0.46 | DD | Dupont De Nemours | PairCorr |
0.45 | CVX | Chevron Corp | PairCorr |
0.34 | MMM | 3M Company | PairCorr |
Related Correlations Analysis
Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
Correlation Matchups
Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Neurocrine Stock performing well and Neurocrine Biosciences Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Neurocrine Biosciences' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
---|---|---|---|---|---|---|---|---|---|---|
AMPH | 1.59 | (0.52) | 0.00 | (1.43) | 0.00 | 3.23 | 14.01 | |||
COLL | 1.73 | 0.03 | 0.03 | 0.04 | 1.93 | 3.47 | 18.67 | |||
IRWD | 4.14 | (0.95) | 0.00 | (0.56) | 0.00 | 5.67 | 52.86 | |||
ANIP | 1.66 | 0.30 | 0.15 | 0.24 | 1.79 | 3.04 | 18.94 | |||
DCPH | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
ALKS | 1.32 | 0.21 | 0.17 | 0.46 | 1.24 | 3.78 | 10.24 | |||
AVDL | 2.47 | (0.24) | 0.00 | (0.23) | 0.00 | 5.12 | 30.76 | |||
ITCI | 1.59 | 0.74 | 0.90 | (7.72) | 0.00 | 2.17 | 34.42 | |||
DVAX | 1.05 | 0.12 | 0.10 | 0.75 | 1.36 | 2.36 | 7.23 | |||
PCRX | 2.09 | 0.38 | 0.16 | 0.93 | 2.20 | 4.65 | 16.33 |
Neurocrine Biosciences Corporate Management
Julie Cooke | Chief People Officer | Profile | |
Matthew Abernethy | Chief Officer | Profile | |
Eric Benevich | Chief Commercial Officer | Profile | |
Darin Lippoldt | Chief Legal Officer | Profile | |
Jude Onyia | Chief Officer | Profile | |
Dimitri Grigoriadis | Chief Research Officer | Profile | |
Kyle Gano | Chief Business Development Officer | Profile |